-
Ofatumumab Better at Treating Relapsing MS Than Aubagio, Phase 3 Trial Data Show
Results from two Phase 3 studies found ofatumumab injections more effective than oral Aubagio at reducing relapses and slowing progression in relapsing MS. Click here to learn more.
What do you think of this news?
Sorry, there were no replies found.
Log in to reply.